[Editor's Note: A version of this article by Tim Casey originally appeared in In Vivo, Medtech Insight's sister publication, as well as AIS Health’s Health Plan Weeklypublished by Norstella, Medtech Insight'sparent company.]
Prescription digital therapeutics (PDT) companies like Pear Therapeutics, Better Therapeutics and Akili Interactive Labs are facing reimbursement challenges and an investment
Key Takeaways
-
Prescription digital therapeutics (PDTs) companies that went public via SPAC are struggling to stay afloat.
-
The companies and the industry trade group primarily attribute PDTs' disappointing uptake to lack of reimbursement and payers' resistance to innovation